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Studies of antinuclear antibodies (ANA) were carried out in 39 cases of systemic sclero-
derma and for comparison in 19 cases of systemic lupus erythematosus <SLE) and 4 of mixed 
connective tissue disease (MCTD) using indirect immunofluorescence (IFl methods under 
standard conditions. The results on three different substrates- monkey esophagus, guinea-
pig lip and rat liver-are reported. In 48.7% of scleroderma cases ANA showed a substrate 
specificity. The highest percentage of positive resuJts in scleroderma was obtained on 
monkey esophagus (97.4~) and the lowest on rat liver (61.517t). In SLE and MCTD, in 
contrast. only about 13% of the sera displayed such specificity. If only sera with substrate 
specificity are considered. the positive resul ts on monkey esophagus and rat liver are 94.7o/c 
and 21.1%. respectively. 
Titers of sera reacting positively on 2 or 3 substrates were mostly in agreement. altbough 
some sera both in systemic scleroderma and SLE showed higher titers on monkey esopha-
gus. The IF pattern was usually the same regardless of the substrate. 
Tests for ANA in scleroderma should be performed on at least 2 substrates simultane-
ously. 
While there is a general agreement in the litera-
tw·e that antinuclear antibodies <ANAl are detect-
able in systemic lupus erythematosus (SLE> in 95 
to 100%- of the cases 11-6]. extremely discrepant 
results have been reported in scleroderma with 
values ranging from 0% 17.8]. 48%- 19]. 60~ ll.lOJ. 
76% 11 U 2]. 78% 113]. to about 859£ in repeated 
examinations [14,151 or even 92.5ck [161. One or 
more of three facUlrs may be responsible for these 
discrepancies: fluctuations of the titers at various 
time intervals I 14-161. the conjugate characteris-
tics 1171. andfor the tissue antigens used . The lat-
ter is the subject of this investigation. 
In order to standardize methods, conjugates 
were defined in terms of content of antibodies 
(equal to or greater than 10% antibody or 4 units/ 
1 %· protein). molar ralio of fluorescein to protein 
(in the range of 2 to 4 l. and dilutions for use 
depending on antibody assays and on the results of 
chessboard titration 1181. Quick-frozen. unfLXed 
rat liver was used as a standard substrate in the 
process of elaborating these methods simply be-
cause it is readily available and its immunofluo-
rescence (IF) pattern is clear. In the course of 
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routine use of monkey esophagus for IF tests. we 
have noted that this substrate permits detection of 
ANA in more of the sera of scleroderma patients 
tha n rat liver . We, therefore. have undertaken a 
comparative study on the frequency of ANA in 
scleroderma using various antigenic substrates. 
MA TERlALS AND METHODS 
The material studied consisted of 39 cases of systemic 
scleroderma and, as positive controls . 19 cases of SLE 
and 4 cases of mixed connective tissue disease 
tMCTD>. Negative controls consisted of79 healthy per-
sons. None of their sera y ielded significant lV~A on the 
substrates tested. Weak homogeneous ANA at tite rs of 
10 and 20 were not regarded as significant. The age 
ranges of the control subjects and the patients studied 
were essentially comparable. Also the mean ages of the 
controls and SLE patients were comparable (29.0 and 
30.5 years) though the scleroderma and MCTD patien ts 
tended to be older !mean age 40.6 years). 
In all cases the same anti-IgG conjugate with a molar 
fluorescein/protein ratio of2.4 and an antibody content 
of 4 units/1 't protein was used at a dilution containing 
1/8 unit/mi. i.e .. a t a l/32 dilution. Monkey esophagus. 
guinea-pig lip, and rat liver were used as antigenic 
substrates. 
The test was performed in routine manner [18) with 
unfixed quick-frozen tissue. A serum which reacted 
with all substrates served as a positive control. All tests 
were read with an American Optical microscope with 
an HBO .200 mercury vapor light source and a to ric lens 
condenser. 
RESULTS 
The results of substrate specificity tests are 
summarized in Table I. In about. 50~ of sclero-
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derma cases (19 of 39) ANA could be detected on 
some but not all antigenic substrates. In contrast, 
such substrate specificity manifested itself with 
only about 13% (3 of23) of the SLE and MCTD sera 
tested. 
Figure 1 gives the percentage of ANA detected 
on different substrates in the 39 sera of sclero-
derma patients. Of the sera with substrate speci-
ficity, 94.7% were positive with monkey esopha-
gus, 52.6% with guinea-pig lip, and only 21.1% 
with rat liver. The largest number of sera (10) 
reacted with monkey esophagus and guinea-pig 
mucosa, and the smallest number (1) only with rat 
liver. It was possible to detect ANA in all of these 
sera by performing tests on both monkey esopha-
gus and rat liver sections. 
Titers of sera reacting positively on 2 or 3 sub-
strates were mostly in agreement. However , sera 
of 4 of 20 scleroderma patients which reacted with 
all the substrates had different titers on the anti-
genic substrates tested (Tab. II. Fig. 2). 
Almost all of the SLE and MCTD sera tested in 
this study reacted with at least 2 substrates (rat 
liver and monkey esophagus) and most with all 
TABLE I. Substrate specificity of ANA in various 
collagen diseases 
Disease No. of cases 
Scleroderma 39 
SLE" 19 
MCTD" 4 
Substrate specificity 
Yes 
191' 
3r 
0 
No 
20 
16 
4 
" SLE = systemic lupus erythematosus; MCTD 
mixed connective tissue disease. 
b By x2 analysis the substrate specificity in sclero-
derma was statistically higher than in SLE or MCTD. 
(x 2 = 10.1; n = 1; p < 0.005). 
•· The serum of one patient reacted only with monkey 
esophagus and rat liver. The serum of a second patient 
reacted only with monkey esophagus. The serum of a 
third patient reacted with both monkey esophagus and 
guinea-pig lip. and not with rat liver. 
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FJG. 1. Systemic scleroderma. Detectability of ANA 
on various substrates. 
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TABLE IT. Differences in ANA titers on various 
substrates in collagen diseases 
No. of Differences in ANA titers Disease 
cases• Yes No 
Scleroderma 20 4'' 16 
SLE" 16 Sb ll 
MCTD" 4 0 4 
" Only cases with no substrate specificity. Short no-
tations as for Table I. 
1
' Data for scleroderma are not statistically different 
from those for SLE or MCTD. (x2 = 0.009; n = 1; p = 
0.9). See Figure 2 for graphic comparisons of titers. 
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FJG . 2. Comparison of ANA titers on different sub-
strates. T op: systemic scleroderma. Bottom: SLE. D = 
Monkey esophagus; IB =guinea-pig lip; • =rat liver. 
three. The titers were comparable in most cases 
but some discrepancies did occur in 5 of 16 sera 
tested (Tab. II. Fig. 2). 
In most cases of scleroderma and SLE. the ANA 
patterns were similar on substrates tested (Tab. 
Ill). In 15 of20 cases of scleroderma (75%) the ANA 
pattern was speckled and/or nucleolar, while in 13 
of 16 SLE patients (81 %) the ANA patterns were 
either homogeneous or peripheral. This difference 
is a highly significant one ()(~ = 17 .3; n = 1; p < 
0.005). 
DISCUSSION 
The findings in this study indicate that. in con-
trast to SLE 120-23] ANA sera of scleroderma 
patients display substrate specificity in a consider-
able proportion of cases. This appears to be one of 
the reasons for the markedly discrepant results 
reported from laboratories using various antigenic 
substrates [1.7-16]. From the basic immunologic 
point of view these resul ts indicate that the ob-
served substrate specificity manifested primarily 
by sera of systemic sclerosis patients may be due 
either to species-specific or to organ-specific ANA 
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TABLE III. Differences in pattern of uarious substrates 
Differences in pattern Patterns 
Disease No. of cases" Yes No Speckled Homogene- Peripheral Others 
ous 
Scleroderma 20 2* 18b 12 3 0 3 
SLE" 16 l** 15 2 10 3 0 
MCTD" 4 0 4 2 0 0 2 
" Only cases with no substrate specificity. Short notations as for Table I. 
11 Scleroderma and SLE-MCTD data are not statistically different <x" "" 0.325; n = 1). 
* One serum wit.h speckled pattern on guinea-pig lip and homogeneous pattern on monkey esophagus and rat 
liver. Another serum showed an homogeneous pattern on guinea-pig lip and a speckled pattern on monkey 
esophagus and rat liver. 
*'*Serum with speckled pattern on guinea-pig lip and rat liver. homogeneous pattern on monkey esophagus. 
or to ANA which had both types of specificity. 
From a practical point of view, our observations 
indicate that monkey esophagus yields the highest 
percentage of ANA. However, a small number of 
sera fail to react with it, while reacting only with 
rat liver. Hence, there is no ideal substrate for the 
detection of ANA in scleroderma. The method of 
choice appears to be the use of at least 2 different 
substrates simultaneously. notably monkey 
esophagus and rat liver. To achieve reproducible 
results with these substrates. standardized test 
conditions need to be used. 
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